SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by D’Cruz, D P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by D’Cruz, D P
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Mycophenolate mofetil in systemic vasculitis

D P D’Cruz

The Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, London, UK, david.d'cruz{at}kcl.ac.uk

The systemic vasculitides are a group of potentially life-threatening multi-system autoimmune connective tissue diseases characterized by vascular inflammation. The gold standard therapies include corticosteroids and cyclophosphamide as induction therapy and other agents such as azathioprine and methotrexate to maintain remission. Mycophenolate mofetil (MMF) is increasingly being used in autoimmune disorders and this article reviews the use of this agent in the systemic vasculitides.

Key Words: mycophenolate mofetil • systemic vasculitis • Wegener’s granulomatosis

Lupus, Vol. 14, No. 3 suppl, s55-s57 (2005)
DOI: 10.1191/0961203305lu2120oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
J. Posalski, M. Ishimori, D. Wallace, and M. Weisman
Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
Lupus, May 1, 2009; 18(6): 516 - 521.
[Abstract] [PDF]

Home page
 LupusHome page
R Foster, E Rosenthal, S Marques, P Vounotrypidis, S Sangle, and D D'Cruz
Primary systemic vasculitis: treatment of difficult cases
Lupus, March 1, 2006; 15(3): 143 - 147.
[Abstract] [PDF]


Advertisement